Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Donor CD33 CAR-NK in Relapsed/Refractory AML
NCT07026942Phase 2Not yet recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Apr 2026
- Primary completion
- Jul 2032
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Universal donor derived CD33 CAR-NK in acute myeloid leukemia (AML), sponsored by Nationwide Children's Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Universal donor derived CD33 CAR-NK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07026942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026942.